Skip Navigation
Skip to contents

JLC : Journal of Liver Cancer

OPEN ACCESS
SEARCH
Search

Articles

Page Path
HOME > J Liver Cancer > Volume 16(1); 2016 > Article
Case Report Regression of Advanced Hepatocellular Carcinoma with Lung Metastasis in Response to Sorafenib
Dae-ha Kim, Gee ho Min, Dong-won Lee, Ke Ryun Ahn, Ji Hye Kim, Snag-Jun Suh, Young Kul Jung, Hyung Joon Yim
Journal of Liver Cancer 2016;16(1):57-62
DOI: https://doi.org/10.17998/jlc.16.1.57
Published online: March 31, 2016
Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea
  • 1,090 Views
  • 6 Download
  • 0 Crossref
  • 0 Scopus

Sorafenib is a multi-targeted tyrosine kinase inhibitor that inhibits Raf kinase and the vascular endothelial growth factor receptor intracellular kinase pathway and is the first agent to demonstrate a statistically significant improvement in overall survival for patients with advanced hepatocellular carcinoma (HCC). However, there were few cases of partial or complete response reported in the previous studies. We herein report a case of dramatic partial response in a patient who had advanced HCC with multiple lung metastasis and portal vein thrombosis treated with sorafenib.


JLC : Journal of Liver Cancer